About: Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations
source	Elsevier; PMC
abstract	Abstract So far, available evidence suggests that patients with inflammatory bowel disease (IBD) are not at greater risk for developing COVID-19 infection. In regard to patients with IBD remission: 5-aminosalycylates (5-ASAs) do not increase the risk for infection and should be continued. There is no need to suspend them or lower the dose. Immunomodulating drugs, such as thiopurines and methotrexate, should be continued, without modifying doses (even in patients with positive SARS-CoV-2 infection). No type of biologic therapy should be suspended, unless there are signs of COVID-19. Regarding patients with IBD activity: the oral and/or topical 5-ASA dose should be optimized in cases of disease relapse. Budesonide MMX should be considered in cases of mild-to-moderate activity, to avoid systemic steroid use. Systemic steroids should be avoided whenever possible because doses above 20 mg per day have an immunosuppressive effect, which could increase susceptibility to any type of infection, including COVID-19. The combined use of thiopurines with steroids and/or tumor necrosis factor (TNF) monoclonal antibodies should also be avoided because those combinations can increase the risk for infections, including COVID-19. Finally, biologic treatment with anti-TNF-alpha agents or any other mechanism of action, such as anti-integrins or anti-interleukins, should be suspended if patients become infected with SARS-CoV-2. The drugs can be restarted once the infectious process is resolved.
has issue date	2020-06-28(xsd:dateTime)
bibo:doi	10.1016/j.rgmxen.2020.05.001
has license	els-covid
sha1sum (hex)	27ecaffee33a44240979b5ecd1b1472b2dbf6ae2
schema:url	https://doi.org/10.1016/j.rgmxen.2020.05.001
resource representing a document's title	Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations
has PubMed Central identifier	PMC7321053
resource representing a document's body	covid:27ecaffee33a44240979b5ecd1b1472b2dbf6ae2#body_text
is schema:about of	named entity 'virus' named entity 'SARS-CoV-2' named entity 'ustekinumab' named entity 'coronavirus' named entity 'vedolizumab' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software